Week in Review: JHL Biotech Signs $257 Million Biosimilar Deal with Sanofi

JHL Biotech, a Taiwan-China biotech, signed a $257 million partnership giving Sanofi rights to market a JHL rituximab biosimilar with China the first market; BioAtla of San Diego and Beijing will receive $100 million from Sinobioway for China rights to four BioAtla drug candidates; Aier Eye Hospital Group of Changsha will pay $84 million to buy out its partners in nine hospitals; Mandarin Capital Partners of China paid $17.4 million to acquire a majority stake in an Italian CMO, Mipharm SpA; GrandOmics, a Beijing third-generation sequencing company, raised $14 million in an A funding round; Beijing's BeiGene will collaborate with Cancer Genetics of New Jersey, a precision medicine company; Qiming Venture Partners led a Series B funding in MicroTech Medical, a Hangzhou diabetes device company; Mederi Therapeutics of Connecticut received CFDA approval for its non-surgical GERD treatment device; and AstraZeneca announced positive results from a Phase III trial of Tagrisso in patients with relapsed non-small cell lung cancer, including a China cohort. More details.... Stock Symbols: (TWO: 6540) (NYSE: SNY) (SHZ: 300015) (NSDQ: BGNE) (NSDQ: CGIX) (NYSE: AZN) Share this with colleagues: // //